NeuroNate said:The mechanism is more central than most summaries suggest.
Filing a mild objection. Mild because I might be wrong; an objection because nobody has addressed the case that does not fit. The "earlier than weight loss explains" argument is weaker than this thread makes it sound. Blood pressure and inflammatory markers move fast and are downstream of early weight loss, so the mechanism is not as cleanly separable as the summaries imply.
The figures, for anyone assembling their own picture. Numbers worth memorising for this class: Tmax one to three days for the weekly peptides, terminal half-life about a week for semaglutide and about five days for tirzepatide, steady state at four to five half-lives, subcutaneous bioavailability high enough that site choice is irrelevant.
VendorMark said:The "earlier than weight loss explains" argument is weaker than this thread makes it sound.
Continuous metabolic monitoring dashboard for cardiovascular risk — I track everything in a spreadsheet and here's the month-over-month trend for my key markers:
Weight: consistent downtrend, -1.6 lbs/week average
Fasting glucose (finger stick): stable at 85 mg/dL
Blood pressure (home): 116/75 average
Resting heart rate: 65 bpm (down from 81)
Waist circumference: down 15 inches total
The resting heart rate improvement correlates with cardiovascular fitness gains. Everything is moving in the right direction.
PeptideDetective — Independent Peptide Analytics
Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.
View ResultsOne thing that is still open after fiona_VT’s answer:
Which effects tachyphylax and which persist, because the answer explains why tolerability improves while the appetite effect keeps working?
Reporting back.
Closing this out: the trough rather than the peak explains the pattern I was seeing on day six, which I had been blaming on the vial.